Consun Pharmaceutical Group Limited

1681

KYG2524A1031

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:12 14/06/2024 BST			5-day change	1st Jan Change
5.7 ^HKD	-1.21%		-11.63%	+19.50%

05-31	Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023	CI
05-24	Consun Pharmaceutical Group Limited Announces Special Dividend, Payable on 21 June 2024	CI

Consun Pharmaceutical Group Limited Appoints Lin Sheng as Non-Executive Director, Effective April 1, 2016

March 31, 2016 at 12:59 am

The board of directors of Consun Pharmaceutical Group Limited announced that Mr. LIN Sheng has been appointed as a non-executive Director of the company with effect from 1 April 2016. Mr. LIN, aged 41, joined Hony Capital Fund 2008, L.P. in April 2003.

Latest news about Consun Pharmaceutical Group Limited

Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023	05-31	CI
Consun Pharmaceutical Group Limited Announces Special Dividend, Payable on 21 June 2024	05-24	CI
Consun Pharmaceutical Group Announces Special Dividend on 10th Anniversary of Joining HK Bourse	05-24	MT
Consun Pharmaceutical to Grant About 8.2 Million Share Options Under New Program	05-07	MT
Consun Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on or About 21 June 2024	04-29	CI
Consun Pharmaceutical Group Sees 15% Increase in 2023 Profit	03-29	MT
Consun Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 21 June 2024	03-28	CI
Consun Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Consun Pharmaceutical Group Limited Announces Board and Committee Changes	03-25	CI
Consun Pharma CEO Steps Down	01-18	MT
Consun Pharmaceutical Group Limited Announces CEO Changes	01-17	CI
Consun Pharmaceutical Group Limited Announces Management Changes	01-17	CI
Consun Pharmaceutical's Unit Starts Construction of Second Chinese Medicine Granule Plant	26/10/23	MT
Consun Pharmaceutical's H1 Profit Rises on Higher Revenue	24/08/23	MT
Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 20 September 2023	24/08/23	CI
Consun Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23	CI
Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2022	31/05/23	CI
Consun Pharmaceutical Group Limited Declares Final Dividend for the Year Ended December 31, 2022	27/04/23	CI
Chinese Regulator Approves Consun Pharmaceutical's Clinical Trial for Kidney Disease Treatment	17/04/23	MT
Consun Pharmaceutical Group Limited Receives Approval for Clinical Trial of Drug for SK-07 Injection	16/04/23	CI
Consun Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23	CI
Consun Pharmaceutical Group Limited Proposes to Pay A Final Dividend for the Year Ended December 31, 2022, Payable on or About June 21, 2023	23/03/23	CI
Consun Pharmaceutical Group Sees Surge in 2022 First-Half Profit	23/09/22	MT
Consun Pharmaceutical's H1 Profit Rises on Higher Revenue	26/08/22	MT
Consun Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2022	26/08/22	CI

Chart Consun Pharmaceutical Group Limited

Duration

Period

Chart Consun Pharmaceutical Group Limited

More charts

Company Profile

Consun Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The pharmaceutical products of the Company include kidney medicines, contrast medium and others. The Companyâs subsidiaries include Brilliant Reach Group Limited, Century International Develop Limited and Grand Reach Company Limited. Through its subsidiaries, the Company is also engaged in the research and development of pharmaceutical products.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Consun Pharmaceutical Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.294 CNY

Average target price

7.615 CNY

Spread / Average Target

+43.83%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CONSUN PHARMACEUTICAL GROUP LIMITED	+19.50%	603M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.37%	43.54B
OTSUKA HOLDINGS CO., LTD.	+19.44%	21.78B
SANDOZ GROUP AG	+17.85%	15.38B
CIPLA LIMITED	+25.55%	15.12B
ZYDUS LIFESCIENCES LIMITED	+60.99%	13.36B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-15.02%	6.38B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.17%	5.32B

Generic Pharmaceuticals